Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 30, 2025The Ukrainian Journal of Clinical Surgery

Long–term survival of patients after multimodal treatment of stage IIIA(N2) non–small cell lung cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

VZV D ZakharychevPGProkip GordiichukBBB. O. Borysiuk

Discussion

Loading...

Member takes

Overview

Comparative study shows neoadjuvant chemoradiotherapy improves overall and recurrence-free survival in stage IIIA(N2) patients.

Key Points

  • Neoadjuvant chemoradiotherapy resulted in the highest overall five-year survival rate of 30.1%.
  • Patients with complete tumor response after neoadjuvant chemoradiotherapy lived significantly longer than those receiving other treatments.
  • Observational analysis of 43 patients for chemoradiotherapy versus 200 for chemotherapy shows improved outcomes for chemoradiotherapy.
  • Long-term survival rates highlight the effectiveness of neoadjuvant chemoradiotherapy in treating severe lung cancer.

Cite This Study

Zakharychev et al. (2025) studied this question.

synapsesocial.com/papers/68af2ef0cf1dd9ea359e6f6fhttps://doi.org/10.26779/2786-832x.2025.4.45
View Full Paper
Ask AI
Bookmark
Share